Journey Medical (NASDAQ:DERM) Upgraded at Wall Street Zen

Journey Medical (NASDAQ:DERM - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday.

DERM has been the topic of a number of other research reports. Alliance Global Partners restated a "buy" rating on shares of Journey Medical in a research note on Thursday, May 15th. Industrial Alliance Securities set a $10.50 price target on shares of Journey Medical in a research note on Thursday, March 27th.

Journey Medical Trading Up 0.6%

Shares of DERM traded up $0.04 during midday trading on Friday, reaching $7.18. The stock had a trading volume of 134,465 shares, compared to its average volume of 88,595. The firm has a 50 day simple moving average of $7.04 and a 200-day simple moving average of $5.76. Journey Medical has a one year low of $3.54 and a one year high of $8.25. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.03 and a current ratio of 1.34.

Journey Medical (NASDAQ:DERM - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. The firm had revenue of $13.14 million for the quarter, compared to the consensus estimate of $12.05 million. Journey Medical had a negative return on equity of 52.03% and a negative net margin of 14.76%. On average, equities analysts expect that Journey Medical will post -1.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Journey Medical news, CEO Claude Maraoui sold 4,834 shares of the stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $6.84, for a total transaction of $33,064.56. Following the transaction, the chief executive officer owned 2,348,313 shares in the company, valued at $16,062,460.92. This represents a 0.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 15.03% of the company's stock.

Institutional Investors Weigh In On Journey Medical

Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new position in Journey Medical during the 1st quarter worth $110,000. Titleist Asset Management LLC increased its position in shares of Journey Medical by 18.3% in the first quarter. Titleist Asset Management LLC now owns 12,900 shares of the company's stock worth $76,000 after purchasing an additional 2,000 shares during the period. Pale Fire Capital SE acquired a new position in Journey Medical in the first quarter valued at about $161,000. Cambridge Investment Research Advisors Inc. raised its stake in Journey Medical by 3.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 338,050 shares of the company's stock valued at $1,994,000 after purchasing an additional 9,938 shares in the last quarter. Finally, Tang Capital Management LLC bought a new stake in Journey Medical during the fourth quarter worth about $6,747,000. 7.25% of the stock is currently owned by institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.